MoonLake gains FDA alignment on drug approval pathway for hidradenitis suppurativa treatment

Filed May 11, 2026 · Period ending May 10, 2026 · ~1 min read

Key Changes

• high

  FDA and MoonLake aligned on submission plans and label strategy for sonelokimab in hidradenitis suppurativa following final pre-BLA meeting, clearing path toward marketing application.

  Item 8.01 view on EDGAR →
• medium

  Company announced Q1 2026 financial results for quarter ended March 31, 2026 via press release; specific figures not disclosed in 8-K filing.

  Item 2.02 verify on EDGAR →